Several other analysts have also recently issued reports on GKOS. Piper Jaffray Cos. reissued a buy rating on shares of Glaukos Corp. in a research report on Sunday, July 17th. Zacks Investment Research cut shares of Glaukos Corp. from a buy rating to a hold rating in a research report on Tuesday, July 5th. Cantor Fitzgerald assumed coverage on shares of Glaukos Corp. in a report on Thursday, June 2nd. They issued a buy rating and a $35.00 target price on the stock. Finally, Roth Capital raised their target price on shares of Glaukos Corp. from $36.50 to $41.00 and gave the company a buy rating in a report on Tuesday, August 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $37.80.
Glaukos Corp. (NYSE:GKOS) traded down 0.43% on Tuesday, reaching $39.09. 42,968 shares of the company’s stock were exchanged. The stock’s market cap is $1.29 billion. The firm has a 50 day moving average of $33.29 and a 200-day moving average of $26.79. Glaukos Corp. has a one year low of $14.25 and a one year high of $39.82.
Glaukos Corp. (NYSE:GKOS) last issued its quarterly earnings results on Monday, August 1st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.10. The business had revenue of $28.60 million for the quarter, compared to analysts’ expectations of $24.45 million. Glaukos Corp. had a negative net margin of 1.23% and a negative return on equity of 1.14%. The business’s quarterly revenue was up 60.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.30) earnings per share. Equities research analysts forecast that Glaukos Corp. will post $0.10 EPS for the current fiscal year.
In other Glaukos Corp. news, CEO Thomas William Burns sold 162,254 shares of the stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.07, for a total value of $4,878,977.78. Following the transaction, the chief executive officer now directly owns 1,388 shares in the company, valued at $41,737.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Richard L. Harrison sold 5,700 shares of the firm’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $30.00, for a total transaction of $171,000.00. Following the transaction, the chief financial officer now owns 7,088 shares in the company, valued at $212,640. The disclosure for this sale can be found here. 36.80% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Glaukos Corp. by 182.7% in the second quarter. Bank of New York Mellon Corp now owns 82,790 shares of the company’s stock worth $2,413,000 after buying an additional 53,503 shares during the period. Gilder Gagnon Howe & Co. LLC raised its position in shares of Glaukos Corp. by 129.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,141,840 shares of the company’s stock worth $33,296,000 after buying an additional 643,966 shares during the period. CAM Group Holding A S acquired a new position in shares of Glaukos Corp. during the second quarter worth about $2,187,000. BP PLC acquired a new position in shares of Glaukos Corp. during the second quarter worth about $426,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Glaukos Corp. during the second quarter worth about $614,000. Institutional investors and hedge funds own 71.91% of the company’s stock.
Glaukos Corp. Company Profile
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.
Receive News & Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related companies with MarketBeat.com's FREE daily email newsletter.